End-To-End Support To Advance Gene Therapies For Rare Retinal Diseases

When a promising therapeutic candidate for rare inherited retinal diseases was spun out of an academic medical center, an emerging biotech company faced the challenge of advancing the program efficiently while adhering to an accelerated timeline. They needed a knowledgeable and agile partner to provide critical analytical testing, ensuring the product met regulatory and quality standards.

Labcorp played a pivotal role, offering expertise across multiple functional areas, from early analytical assessments to later-stage clinical operations. As the biologic progressed toward the clinic, Labcorp’s comprehensive support helped streamline development, accelerate regulatory submissions, and optimize trial execution. Learn how Labcorp’s integrated solutions enabled the biotech to navigate complex development hurdles and successfully advance their innovative therapy.